Why Not Wait?

Most men with enlarged-prostate symptoms are told their disease is “benign” and can be managed with watchful waiting or medication for as long as needed. The clinical evidence tells a different story.

The premise to reconsider

Benign prostatic hyperplasia (BPH) is called benign because it isn’t cancer. But “benign” was never meant to mean “harmless if ignored.” For many men, the years between first noticing symptoms and finally treating them definitively are years of accumulated cost — to sleep, to sexual function, to mood, to falls and fracture risk, to the bladder itself, and to the eventual surgical outcome when surgery is finally chosen.

This page makes the case that, once symptoms are real and medication is on the table, the better decision for many men is to consider surgery sooner rather than later. It is the opposite of the message most patients hear, and it is grounded in the published evidence.

It is also worth saying clearly: not every man needs surgery. A short section at the end addresses when continued waiting is the right call. The point is not “everyone should be operated on.” The point is that the default of “stay on medication and wait” has been treated as costless when it isn’t.

The prostate does not shrink

The first thing to know is that the gland doesn’t get smaller on its own. In the Olmsted County study — the longest-running community cohort following men with BPH — 631 men were followed with serial transrectal ultrasound over seven years. Predicted prostate growth was approximately 1.6% per year across every age stratum, and men who started with larger prostates grew faster.¹

This means the prostate you have today is the smallest one your surgeon will ever operate on. A 60-gram gland at age 60 is, on average, an 80-gram gland at age 70. Mild obstruction tends to become moderate, then severe.

Holmium laser enucleation of the prostate (HoLEP) is size-independent — it works on glands from 30 grams to 300+ grams. But the surgery is technically easier, faster, and lower-risk in a smaller gland. Recovery is faster. The bladder has spent fewer years compensating against an obstruction. The case for early intervention starts here: the natural history is one of slow, asymptomatic enlargement that doesn’t reverse.

Untreated LUTS costs more than urination

Lower urinary tract symptoms (LUTS) are usually framed in the clinic as a urination problem: a weaker stream, getting up at night, urgency, hesitancy. That framing understates what the data actually show.

Sleep. Nocturia — getting up two or more times a night to urinate — is itself an independent risk factor for impaired next-day cognition and for all-cause mortality in older men.² Most men with moderate-to-severe LUTS have nocturia. Years of fragmented sleep are not a minor cost.

Mood. In the EpiLUTS study (population-based, n>14,000 across three countries), men with moderate-to-severe LUTS had a roughly doubled prevalence of clinically meaningful depressive symptoms and notably higher anxiety scores — independent of age and comorbidities (other ongoing medical conditions).³

Sex. In the Multinational Survey of the Aging Male (MSAM-7), the severity of LUTS predicted erectile dysfunction and ejaculatory dysfunction more strongly than diabetes did, and the relationship was dose-dependent.⁴ Patients often discover, after definitive BPH surgery, that what they assumed was age-related erectile decline tracked tightly with their bladder symptoms.

Falls and fractures. Older men with nocturia have roughly a 1.2- to 2-fold increased risk of falls compared with men who sleep through the night, and the falls are disproportionately on the way to or back from the bathroom.⁵ In community-dwelling older men, two or more episodes of nocturia per night independently predicts hip fracture and other fragility fractures.⁶

None of this is exotic. These are the published, replicated, population-level consequences of leaving moderate symptoms untreated for years. The conventional reassurance — “BPH won’t kill you” — is technically true and clinically misleading. It misses everything BPH actually does.

Medication is not a free buffer

Once a man has bothersome symptoms, the standard first move is medication: an alpha-blocker (tamsulosin, alfuzosin, doxazosin), a 5-alpha-reductase inhibitor (finasteride, dutasteride), or both. There’s nothing wrong with this — for many men it works long enough to be worth doing. But it is not, as is sometimes implied, a cost-free way to delay a decision.

Most men stop taking them. Roughly half of men prescribed an alpha-blocker have discontinued within 12 months, and roughly half of men prescribed a 5-ARI (a prostate medication that slowly shrinks the gland, e.g. finasteride) have discontinued within 24 months, in real-world cohorts.⁷⁸ The reasons cited are unsurprising: side effects, cost, no perceived benefit, the daily-dosing burden, and symptom progression despite therapy.

The improvement most men get is modest. Across the major BPH medical-therapy trials, only about 30% of men achieve a clinically meaningful improvement in symptom score on monotherapy.⁹ Combination therapy does better but adds side effects.

The side effects are real. Tamsulosin and other alpha-blockers cause ejaculatory dysfunction in roughly 14–35% of users, persistent orthostatic hypotension (a drop in blood pressure on standing that causes light-headedness) in older men (with an associated rise in serious adverse events including fall-related visits),¹⁰¹¹ and intraoperative floppy iris syndrome that complicates later cataract surgery.¹² Five-alpha-reductase inhibitors cause erectile dysfunction in roughly 5–9% of users, reduced ejaculate volume in a larger fraction, gynecomastia (enlargement of breast tissue), and — in a meaningful minority — sexual side effects that persist after discontinuation.¹³¹⁴ These are not theoretical: they are the symptoms most men hoped medication would help, made worse by the medication.

Long-term safety is debated. Population-level signals have been raised for cardiovascular events with alpha-blockers (notably the ALLHAT doxazosin arm closure in 2000)¹⁵ and for cognitive decline and mood effects with 5-ARIs.¹⁶ These signals are real, but they need to be read carefully — some have been re-analyzed and partially attributed to confounding. The point is not that medications are dangerous in some hidden way; the point is that they are not the cost-free “buy time” intervention they are sometimes presented as.

The serious question is not “are the medications working” but “what am I delaying to, and is the delay worth it?”

What the delay actually costs at the operating table

The most striking single piece of evidence on this question is a study from Izard and Nickel, published in BJU International in 2011.¹⁷ They compared men coming to transurethral resection of the prostate (TURP) — at the time, the standard BPH operation — at three time points: 1988, 1998, and 2008.

The change in why those men were having surgery is staggering. In 1988, essentially zero patients came to surgery because medical therapy had failed; medical therapy as we now know it didn’t yet exist. By 1998, 36% of TURPs were performed for medication failure. By 2008, that number was 87%.

What was happening to those patients while they waited?

• The rate of preoperative urinary retention (being unable to empty the bladder on your own) rose from 22.9% in 1988 to 42.9% in 2008.
• Discharge with an indwelling Foley catheter (a thin, flexible tube that drains urine from the bladder) rose from 3.2% to 28.6%.
• Hydronephrosis (urine backing up and swelling the kidney) at the time of surgery rose from 1.3% to 7.1% (and peaked at 12.5% in the 1998 cohort).
• Postoperative complications rose across the board.

The authors’ conclusion is direct: the window for consistently good outcomes was missed. The patients who eventually came to surgery in 2008 arrived sicker — bladders that had failed to compensate against years of obstruction, kidneys that had begun to back up, surgical complexity that hadn’t been there at the same patient’s first urology visit. Medications hadn’t replaced surgery; they had delayed it, and the delay had a measurable cost.

Subsequent literature has reinforced the same pattern. A 2025 study of men waiting for HoLEP found that 8% developed preoperative complications during the wait — urinary tract infections, cardiac events, episodes of retention — and those complications independently predicted worse postoperative outcomes.¹⁸ The wait itself was a clinical exposure.

What the 2026 guideline says

The American Urological Association released a new BPH guideline on May 7, 2026, replacing the 2021 document and 2023 amendment. The relevant point for this page is this: HoLEP is now formally recognized as a size-independent surgical option, on the short list of procedures that should be considered for any prostate volume.¹⁹ The guideline also names HoLEP, thulium laser enucleation of the prostate (ThuLEP), GreenLight photoselective vaporization (PVP), and prostatic artery embolization together as appropriate considerations for men at higher bleeding risk — patients on anticoagulation (blood-thinning medication), patients who cannot stop antiplatelet (a type of blood thinner, such as aspirin or clopidogrel) therapy, patients with significant bleeding-related comorbidity. The guideline doesn’t tell any individual man when to have surgery, but it does close the case that HoLEP is a fringe procedure or one reserved for the largest glands. It is the option that works at any size, including in patients other procedures shy away from.

When continued waiting is the right call

This page leads with the case for not waiting because that case is rarely made well. It is not the only honest case, and the readers most likely to find this page deserve the full picture.

Continued watchful waiting is reasonable when symptoms are mild and not bothersome to the patient (low International Prostate Symptom Score (IPSS), no behavior modification, no nocturia waking, intact stream, no retention history); when the patient genuinely prefers the side effects of waiting to the recovery from surgery and is making an informed comparison; when life expectancy is short for unrelated reasons; or when a temporary deferral is needed to coordinate with an unrelated medical issue.

“My symptoms are bearable on medication” is not, by itself, the same as “watchful waiting is the right strategy.” It is worth asking, at each annual visit, whether the medication is actually buying anything — measurable symptom improvement that the patient values, stable bladder volume on imaging, no creeping post-void residual (the amount of urine left in the bladder after you finish urinating), no new nocturia — or whether the medication is being continued because the next step has not been openly discussed.

The decision should always be made together with a urologist who knows your specific anatomy and history. This page is not a substitute for that conversation. It is an argument that the conversation is worth having now rather than in five years.

What to do next

If the points on this page sound like your situation — symptoms that have been creeping for years, medication that isn’t quite working, the assumption that waiting is the safe option — it is reasonable to ask for a surgical opinion. Asking for the opinion does not commit you to surgery. It commits you to having the conversation with someone who does the operation often enough to give a clear answer either way.

To schedule a consultation with Dr. Quarrier, call UR Medicine Urology at (585) 275-2838.

References